Search by Drug Name or NDC
NDC 00031-8739-18 ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM 20; 400 mg/20mL; mg/20mL Details
ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM 20; 400 mg/20mL; mg/20mL
ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM is a ORAL SOLUTION in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN.
MedlinePlus Drug Summary
Dextromethorphan is used to temporarily relieve cough caused by the common cold, the flu, or other conditions. Dextromethorphan will relieve a cough but will not treat the cause of the cough or speed recovery. Dextromethorphan is in a class of medications called antitussives. It works by decreasing activity in the part of the brain that causes coughing.
Related Packages: 00031-8739-18Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dextromethorphan
Guaifenesin is used to relieve chest congestion. Guaifenesin may help control symptoms but does not treat the cause of symptoms or speed recovery. Guaifenesin is in a class of medications called expectorants. It works by thinning the mucus in the air passages to make it easier to cough up the mucus and clear the airways.
Related Packages: 00031-8739-18Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Guaifenesin
Product Information
| NDC | 00031-8739 |
|---|---|
| Product ID | 0031-8739_011d653e-0754-40bd-b4c8-2280bdd1953c |
| Associated GPIs | 43997002520905 |
| GCN Sequence Number | 023893 |
| GCN Sequence Number Description | guaifenesin/dextromethorphan LIQUID 100-5 MG/5 ORAL |
| HIC3 | B3T |
| HIC3 Description | NON-OPIOID ANTITUSSIVE AND EXPECTORANT COMBINATION |
| GCN | 53497 |
| HICL Sequence Number | 000223 |
| HICL Sequence Number Description | GUAIFENESIN/DEXTROMETHORPHAN HBR |
| Brand/Generic | Generic |
| Proprietary Name | ROBITUSSIN MAXIMUM STRENGTH COUGH PLUS CHEST CONGESTION DM |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | dextromethorphan hydrobromide, guaifenesin |
| Product Type | HUMAN OTC DRUG |
| Dosage Form | SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 20; 400 |
| Active Ingredient Units | mg/20mL; mg/20mL |
| Substance Name | DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN |
| Labeler Name | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| Pharmaceutical Class | Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Ant |
| DEA Schedule | n/a |
| Marketing Category | OTC MONOGRAPH FINAL |
| Application Number | part341 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00031-8739-18 (00031873918)
| NDC Package Code | 0031-8739-18 |
|---|---|
| Billing NDC | 00031873918 |
| Package | 1 BOTTLE in 1 CARTON (0031-8739-18) / 237 mL in 1 BOTTLE |
| Marketing Start Date | 2016-06-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |